Why Pfizer's 2017 Was Mediocre at Best Post author:Sam Post published:December 12, 2017 Post category:BioPharma Pfizer’s 2017 wasn’t horrible. Just ho-hum. Source: BioSpace You Might Also Like Kindred Bio Announces Proposed Public Offering Of Common Stock July 11, 2017 Biotech Startup Formed by 4 Ex-Pfizer Employees Inks Deal With Former Employer January 22, 2018 AstraZeneca Gets in on ADC Therapeutics' Mega $200M Funding Round October 22, 2017
